Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical gel containing prochlorperazine maleate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing prochlorperazine are listed in tablet, injection and suppository forms. No finished prochlorperazine product of any kind is listed in gel form.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Prochlorperazine maleate is a phenothiazine antipsychotic used for severe nausea and vomiting that a pharmacy may compound when a prescriber orders it.
Prochlorperazine maleate is the maleate salt of prochlorperazine, a conventional (first-generation) antipsychotic of the phenothiazine class. It mainly blocks dopamine D2 receptors in the brain and can also block histamine, acetylcholine and norepinephrine receptors. Prochlorperazine maleate tablets are FDA-approved for control of severe nausea and vomiting, for schizophrenia, and for short-term treatment of generalized non-psychotic anxiety, which the label says is not a first-choice use. Prochlorperazine is also made as rectal suppositories and given by injection. A prescriber might order prochlorperazine maleate compounded when a needed strength or dosage form is not manufactured, when a patient needs a preparation free of a particular inactive ingredient, or as part of a combination. Compounded preparations are not FDA-approved and require a prescription.
Prochlorperazine carries a boxed warning: older adults with dementia-related psychosis treated with antipsychotic drugs have a higher risk of death. Other warnings include tardive dyskinesia (possibly permanent involuntary movements), neuroleptic malignant syndrome, low white blood cell counts, and drowsiness or dizziness that can lead to falls. Do not use it if you are allergic to phenothiazines or heavily sedated by alcohol or other depressants, or for children under 2 years or 20 pounds. It can weaken blood thinners, interacts with propranolol and some blood pressure drugs, and may lower seizure threshold. The label does not recommend it in pregnancy except for severe, intractable vomiting, and newborns exposed late in pregnancy may have movement or withdrawal symptoms. LactMed says occasional short-term use for nausea and vomiting poses little risk to breastfed infants. Call your prescriber at once for fever with stiff muscles or uncontrolled movements; for other side effects, talk to your prescriber or pharmacist.
Prochlorperazine is a first-generation phenothiazine antipsychotic that acts mainly as a D2 dopamine receptor antagonist, with histaminergic, cholinergic and noradrenergic receptor blockade. Oral prochlorperazine undergoes high first-pass metabolism with poor, variable absorption and is metabolized by cytochrome P450 enzymes, so review concomitant inducers and inhibitors (StatPearls). Labeled indications (prochlorperazine maleate tablets, Glenmark): control of severe nausea and vomiting; schizophrenia; and short-term treatment of generalized non-psychotic anxiety, with duration limits because of tardive dyskinesia risk. StatPearls describes oral, intramuscular, intravenous and rectal administration and emergency department use for migraine, which is not an FDA-approved indication; compounded preparations are not FDA-approved. Dosing is per prescriber. Contraindicated in phenothiazine hypersensitivity, comatose states or with large amounts of CNS depressants, pediatric surgery, and children under 2 years or 20 lbs. Extrapyramidal signs may mask Reye's syndrome or other encephalopathy; avoid in children and adolescents whose symptoms suggest Reye's syndrome. Monitor for tardive dyskinesia, neuroleptic malignant syndrome, orthostatic hypotension and falls. In patients with preexisting low WBC or prior drug-induced leukopenia, monitor CBC frequently in the first months and stop at the first decline without another cause.
Wash your hands. Apply the amount on your label to clean, dry skin and spread it in a thin layer. For a metered pump, your label states the number of presses. For a dosing syringe, push the plunger to the mark. Let the gel dry before covering with clothing. Wash your hands afterward and keep the site from touching other people until it has dried. Do not apply to broken skin unless told to.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, away from heat and open flame if it contains alcohol, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)
